DCEP for relapsed or refractory multiple myeloma after therapy with novel agents

Annals of Hematology

Volumn 93, Issue 1, 2014, Pages 99-105

  Park, Silvia ^a   Lee, Su Jin ^a   Jung, Chul Won ^a   Jang, Jun Ho ^a   Kim, Seok Jin ^a   Kim, Won Seog ^a   Kim, Kihyun ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

Multiple myeloma; Novel agents; Salvage regimen

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; LENALIDOMIDE; SEROTONIN ANTAGONIST; THALIDOMIDE;

ADULT; ANEMIA; ANOREXIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTEREMIA; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CANDIDEMIA; CONSTIPATION; DIARRHEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 84891855318     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1952-5     Document Type: Article

References (43)

1. Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF (2013) Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 121:884-892. doi: 10.1182/blood-2012-05-432203
2. Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G (2012) Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 30:2475-2482. doi: 10.1200/JCO.2011.37.4918
3. Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116:679-686. doi: 10.1182/blood-2010-02-268862
4. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492-494
5. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C (2000) Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 109:89-96 (Pubitemid 30340583)
6. Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger W, Badros AZ, Vescio R, Kenvin L, Yu Z, Olesnyckyj M, Zeldis J, Knight R, Anderson KC (2009) Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 114:772-778. doi: 10.1182/blood-2008-12-196238
7. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498. doi: 10.1056/NEJMoa043445 (Pubitemid 41007864)
8. Ciolli S, Leoni F, Casini C, Breschi C, Santini V, Bosi A (2008) The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. Br J Haematol 141:814-819. doi: 10.1111/j.1365-2141.2008.07147.x (Pubitemid 351724874)
9. Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N, Eleftherakis-Papaiakovou E, Tsionos K, Croucher P, Dimopoulos MA (2008) The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 22:2247-2256. doi: 10.1038/leu.2008.235
10. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, Crippa C, Ciccone G, Omede P, Ambrosini MT, Gay F, Bringhen S, Musto P, Foa R, Knight R, Zeldis JB, Boccadoro M, Petrucci MT (2007) Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA - Italian Multiple Myeloma Network. J Clin Oncol 25:4459-4465. doi: 10.1200/JCO.2007.12.3463 (Pubitemid 350063804)
11. Pineda-Roman M, Zangari M, van Rhee F, Anaissie E, Szymonifka J, Hoering A, Petty N, Crowley J, Shaughnessy J, Epstein J, Barlogie B (2008) VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 22:1419-1427. doi: 10.1038/leu.2008.99 (Pubitemid 352006086)
12. Lonial S (2010) Relapsed multiple myeloma. Hematol Am Soc Hematol Educ Program 2010:303-309. doi: 10.1182/asheducation-2010.1.303
13. Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS (2012) An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 119:5661-5670. doi: 10.1182/blood-2012-03-414359
14. Chauhan D, Singh AV, Aujay M, Kirk CJ, Bandi M, Ciccarelli B, Raje N, Richardson P, Anderson KC (2010) A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 116:4906-4915. doi: 10.1182/blood-2010-04-276626
15. Tian Z, Zhao JJ, Tai YT, Amin SB, Hu Y, Berger AJ, Richardson P, Chauhan D, Anderson KC (2012) Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood 120:3958-3967. doi: 10.1182/blood-2012-01-401794
16. Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JC Jr, Fenical W, Ghobrial IM, Groll M, Jensen PR, Lam KS, Lloyd GK, McBride W, McConkey DJ, Miller CP, Neuteboom ST, Oki Y, Ovaa H, Pajonk F, Richardson PG, Roccaro AM, Sloss CM, Spear MA, Valashi E, Younes A, Palladino MA (2011) Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets 11:254-284
17. Siegel D, Dimopoulos MA, Yoon SS et al (2011) Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial. Blood. ASH Annual Meeting Abstracts 118:480
18. Raje N HP, Vogl DT et al (2012) Rocilinostat (ACY-1215), a selective HDAC6 inhibitor, alone and in combination with bortezomib in multiple myeloma: preliminary results from the first-in-humans phase I/II study. Blood (ASH Annual Meeting Abstracts) 120:4061
19. Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M, Zaki MH, Jacques C, Anderson KC (2013) Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 121:1961-1967. doi: 10.1182/blood-2012-08-450742
20. Jakubowiak A (2012) Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives. Semin Hematol 49(Suppl 1):S16-S32. doi: 10.1053/j.seminhematol.2012.05.003
21. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV (2009) Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 27:5008-5014. doi: 10.1200/JCO.2009.23.6802
22. Lazzarino M, Corso A, Barbarano L, Alessandrino EP, Cairoli R, Pinotti G, Ucci G, Uziel L, Rodeghiero F, Fava S, Ferrari D, Fiumano M, Frigerio G, Isa L, Luraschi A, Montanara S, Morandi S, Perego D, Santagostino A, Savare M, Vismara A, Morra E (2001) DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant 28:835-839. doi: 10.1038/sj.bmt.1703240 (Pubitemid 33107610)
23. Zappasodi P, Nosari AM, Astori C, Ciapanna D, Bonfichi M, Varettoni M, Mangiacavalli S, Morra E, Lazzarino M, Corso A (2008) DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients. Transfusion 48:857-860. doi: 10.1111/j.1537-2995.2007.01621.x (Pubitemid 351614901)
24. Novella E, Madeo D, Albiero E, Roberti S, Castaman G, Elice F, Rodeghiero F (2004) Effect of DCEP mobilizing regimen in in vivo purging of PBSC harvests in multiple myeloma. Leuk Lymphoma 45:1497-1499. doi: 10.1080/ 10428190410001663644 (Pubitemid 38701936)
25. Munshi N DK, Jagannath S et al (1996) Dexamethasone, cyclophosphamide, etoposide and cisplatinum (DCEP), an effective regimen for relapse after high-dose chemotherapy and autologous transplantation (AT) [abstract 586a] Blood 88
26. Dadacaridou M, Papanicolaou X, Maltesas D, Megalakaki C, Patos P, Panteli K, Repousis P, Mitsouli-Mentzikof C (2007) Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. J BUON 12:41-44 (Pubitemid 46824672)
27. NCCN (2013) Multiple myleoma. NCCN guidelines version 2
28. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV (2006) International uniform response criteria for multiple myeloma. Leuk Off J Leuk Soc Am Leuk Res Fund UK 20:1467-1473. doi: 10.1038/sj.leu.2404284 (Pubitemid 44264086)
29. Kyle RA, Rajkumar SV (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leuk Off J Leuk Soc Am Leuk Res Fund UK 23:3-9. doi: 10.1038/leu.2008.291
30. Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Larson DR, Kyle RA, Greipp PR (2004) Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 79:867-874. doi: 10.1016/S0025-6196(11)62152-6 (Pubitemid 38879952)
31. Dimopoulos MA, San-Miguel JF, Anderson KC (2011) Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur J Haematol 86:1-15. doi: 10.1111/j.1600-0609.2010.01542.x
32. Kim YK, Sohn SK, Lee JH, Yang DH, Moon JH, Ahn JS, Kim HJ, Lee JJ (2010) Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. Ann Hematol 89:475-482. doi: 10.1007/s00277-009- 0856-x
33. Harousseau JL, Dreyling M (2010) Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v155-v157. doi: 10.1093/annonc/mdq178
34. Gerrie AS, Mikhael JR, Cheng L, Jiang H, Kukreti V, Panzarella T, Reece D, Stewart KA, Trieu Y, Trudel S, Chen CI (2013) D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma. Br J Haematol 161:802-810. doi: 10.1111/bjh.12325
35. Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G (2003) DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 21:2732-2739. doi: 10.1200/JCO.2003.01.055 (Pubitemid 46606319)
36. Srikanth M, Davies FE, Wu P, Jenner MW, Ethell ME, Potter MN, Shaw BE, Saso RM, Dines S, Morgan GJ (2008) Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE. Eur J Haematol 81:432-436. doi: 10.1111/j.1600-0609.2008.01131.x
37. Oriol A (2011) Multiple myeloma with extramedullary disease. Adv Ther 28(Suppl 7):1-6. doi: 10.1007/s12325-011-0079-0
38. Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, Alsayed Y, Waheed S, Haider S, Restrepo A, Van Rhee F, Crowley J, Barlogie B (2012) Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica 97:1761-1767. doi: 10.3324/haematol.2012.065698
39. Calvo-Villas JM, Alegre A, Calle C, Hernandez MT, Garcia-Sanchez R, Ramirez G (2011) Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma. Eur J Haematol 87:281-284. doi: 10.1111/j.1600-0609.2011.01644.x
40. Krauth MT, Bankier A, Valent P, Kalhs P, Drach J (2005) Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib. Leuk Res 29:1473-1477. doi: 10.1016/j.leukres.2005.05.003 (Pubitemid 41562252)
41. Rosinol L, Cibeira MT, Blade J, Esteve J, Aymerich M, Rozman M, Segarra M, Cid MC, Filella X, Montserrat E (2004) Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 89:832-836 (Pubitemid 38981343)
42. Blade J, Perales M, Rosinol L, Tuset M, Montoto S, Esteve J, Cobo F, Villela L, Rafel M, Nomdedeu B, Montserrat E (2001) Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol 113:422-424 (Pubitemid 32523147)
43. Avigdor A, Raanani P, Levi I, Hardan I, Ben-Bassat I (2001) Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. Leuk Lymphoma 42:683-687. doi: 10.3109/10428190109099330 (Pubitemid 32782776)